Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics Reports Additional Data from Promising Brain Cancer Clinical Trial
June 24th, 2009
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, presented promising clinical data from a Phase I trial evaluating ICT-107, the company's dendritic cell-based cancer vaccine product candidate for the treatment of glioblastoma. These data were reported at the American Society of Clinical Oncology Meeting in Orlando, Florida (Abstract #2032), and supplement the preliminary data from the completed clinical trial that the Company reported in December 2008. The Phase I clinical trial of ICT-107 was conducted to evaluate the safety and tolerability of the cancer vaccine in patients with glioblastoma, the most common and malignant type of brain...
Source: Vaccine Weekly (2009-06-24)
|
